Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation

Acta Haematol. 2003;109(1):43-5. doi: 10.1159/000067271.

Abstract

The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibody

Publication types

  • Case Reports

MeSH terms

  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / etiology*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD19 / blood
  • B-Lymphocytes / cytology
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hemoglobins / metabolism
  • Humans
  • Infant
  • Lymphocyte Depletion / adverse effects*
  • Mucopolysaccharidosis I / complications
  • Mucopolysaccharidosis I / therapy
  • Rituximab
  • T-Lymphocytes
  • Transplantation Chimera
  • Transplantation, Homologous / adverse effects
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD19
  • Hemoglobins
  • Rituximab